Dr. Lal Path Labs Ltd.
NSE: LALPATHLABINE600L01024·HealthcareSmallcap 250·www.lalpathlabs.com ↗·Mcap ₹32,271 Cr·Listed 2015
₹1,952.30▼ ₹9.00  (−0.46%)
52W: ₹1,273 – ₹2,039 · Vol: 4.5L shares · Close 25 Sept
Set Alert

Your Screens

the ones you keep on the screener

Ready-made Screens It Passes

each filter against LALPATHLAB's own figure
45th largest of the 145 companies that pass · see them →
✓
debt to equity at most 0.050.00
✓
ROE at least 20%21.8%
30th largest of the 123 companies that pass · see them →
✓
within 10% of its 52-week high98% of the way up
✓
market cap at least ₹5,000 Cr₹32,271 Cr

One or two filters away

which filter, and by how much
59 companies pass it today · see them →
✗
top 100 by market cap#274
✓
made a profit over the last four quarters₹546 Cr
✓
ROE at least 15%21.8%
92 companies pass it today · see them →
✓
made a profit over the last four quarters₹546 Cr
✗
dividend yield at least 3%1.0%
249 companies pass it today · see them →
✓
made a profit over the last four quarters₹546 Cr
✗
P/E at most 1559.1
✓
market cap at least ₹1,000 Cr₹32,271 Cr
262 companies pass it today · see them →
✓
made a profit over the last four quarters₹546 Cr
✗
P/B at most 112.9
135 companies pass it today · see them →
✗
within 10% of its 52-week low98% of the way up
✓
market cap at least ₹5,000 Cr₹32,271 Cr

3 other ready-made screens it misses on every filter or on more than two. All screens →

LALPATHLAB Figuresrebuilt 26 Sept
Market cap₹32,271 Cr
Rank by market cap#274
P/E59.1
P/B12.9
ROE21.8%
Debt to equity0.00
Revenue growth14.3%
Profit growth5.4%
Net margin18.9%
Dividend yield1.0%
Place in its 52-week range98% of the way up
Below its 52-week high0.8%
Daily turnover₹52 Cr

The last four quarters of filings, consolidated where the company files it, and our end-of-day closes. These are the numbers every filter on this page is held against.

Write Your Own
A screen is a line of English: “debt free with roe above 20%”. Keep one, and it is run again every night; this page then shows whether LALPATHLAB passes it.
Open the screener →